All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ADX-914
Therapeutic Area: Immunology Product Name: ADX-914
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: OrbiMed Advisors
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 29, 2020
Details:
Proceeds from the Series B financing will support the advancement of ADX-914 through demonstration of proof-of-mechanism and propel the company’s groundbreaking tissue-targeted complement regulation platform.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tacrolimus
Therapeutic Area: Immunology Product Name: TFFTAC-LAC
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
Company completes dosing of three cohorts with Tacrolimus Inhalation Powder for direct-to-lung delivery of a Thin Film Freezing dry-powder product for prevention of lung transplant rejection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cetirizine HCl
Therapeutic Area: Immunology Product Name: Ceteric Allergy Gummy
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
SGC scientists have developed a suite of technologies that enable the incorporation of various drug compounds into a novel gummy matrix, thus solving drug solubility, stability, and taste issues.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GP1681
Therapeutic Area: Immunology Product Name: GP1681
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Novotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The new clinical trial is designed to evaluate the use of GP1681 as a potential new medicine to treat the severe immune response to COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CDX-0159
Therapeutic Area: Immunology Product Name: CDX-0159
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
First patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria. CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor and inhibits its activity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Neihulizumab
Therapeutic Area: Immunology Product Name: AbGn-168H
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The trial is a multi-dose study of Neihulizumab in SR-aGVHD and follows its successful Phase 1a single-dose study which demonstrated a 77% response rate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): STMC-103H
Therapeutic Area: Immunology Product Name: STMC-103H
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Khosla Ventures
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 22, 2020
Details:
The latest round of capital will go towards supporting clinical proof of concept (POC) trials testing the efficacy of their lead LBP product, STMC-103H.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Desmoglein 3 Chimeric AutoAntibody Receptor T cells
Therapeutic Area: Immunology Product Name: DSG3-CAART
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
The manuscript, titled “Antigen-specific B-cell depletion for precision therapy of mucosal pemphigus vulgaris,” includes the preclinical data that enabled the DSG3-CAART IND submission and opening of the DesCAARTesTM clinical trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tacrolimus
Therapeutic Area: Immunology Product Name: Tac-Lac
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $25.9 million Upfront Cash: Undisclosed
Deal Type: Financing August 11, 2020
Details:
Net proceeds from the financing will be used to accelerate the expansion of the company’s internal development portfolio beyond its programs for Voriconazole and Tacrolimus inhalation powders.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: AQST-108
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
The FDA has granted the Aquestive's AQST-108 Fast Track designation, "first of its kind" oral sublingual film formulation that delivers systemic epinephrine to treat allergic reactions, including anaphylaxis, using the proprietary Aquestive PharmFilm ® technologies.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
